Screener
Bausch Health Companies BHC Salix — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 6:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885590-26-000053
| (in millions) | Three Months Ended March 31, / Salix / 2026 | Three Months Ended March 31, / Salix / 2025 | Three Months Ended March 31, / International / 2026 | Three Months Ended March 31, / International / 2025 | Three Months Ended March 31, / Solta Medical / 2026 | Three Months Ended March 31, / Solta Medical / 2025 | Three Months Ended March 31, / Diversified / 2026 | Three Months Ended March 31, / Diversified / 2025 | Three Months Ended March 31, / Bausch + Lomb / 2026 | Three Months Ended March 31, / Bausch + Lomb / 2025 | Three Months Ended March 31, / Total / 2026 | Total / 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of goods sold (a) | 47 | 43 | 112 | 102 | 53 | 27 | 27 | 30 | 482 | 481 | ||
| Cost of other revenues | — | — | 16 | 17 | — | — | — | — | 1 | 1 | ||
| Selling, general and administrative | 105 | 111 | 63 | 52 | 35 | 28 | 43 | 45 | 439 | 447 | ||
| Research and development | 19 | 17 | 6 | 6 | 8 | 5 | 3 | 3 | 45 | 28 | ||
| Segment profit | $468 | $371 | $88 | $85 | $75 | $53 | $112 | $127 | $277 | $180 | $1,020 | $816 |
| Corporate | (258) | (268) | ||||||||||
| Amortization of intangible assets | (241) | (256) | ||||||||||
| Goodwill impairments | (1,426) | — |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch Health Companies's salix — R&D?
- Bausch Health Companies (BHC) reported salix — R&D of $19M in Q1 2026.
- How has Bausch Health Companies's salix — R&D changed year-over-year?
- Bausch Health Companies's salix — R&D increased by 11.8% year-over-year, from $17M to $19M.
- What is the long-term trend for Bausch Health Companies's salix — R&D?
- Over 3 years (2022 to 2025), Bausch Health Companies's salix — R&D has grown at a 16.5% compound annual growth rate (CAGR), from $50M to $79M.
- What does salix — R&D mean?
- Captures the investment in scientific research, clinical trials, and product development specifically aimed at expanding or maintaining the Salix segment's product pipeline. This metric reflects the company's commitment to long-term innovation and future growth within its specialized therapeutic areas. High investment levels indicate a focus on sustaining a competitive advantage through new product launches.
Ask your AI about Bausch Health Companies's salix — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude